Dr.Reddy's Laboratories Stock Price, News & Analysis (NYSE:RDY)

$38.67 0.39 (1.02 %)
(As of 01/21/2018 01:35 AM ET)
Previous Close$38.67
Today's Range$38.45 - $38.95
52-Week Range$29.83 - $46.95
Volume230,858 shs
Average Volume199,600 shs
Market Capitalization$6.35 billion
P/E Ratio37.54
Dividend Yield0.77%
Beta0.38

About Dr.Reddy's Laboratories (NYSE:RDY)

Dr.Reddy's Laboratories logoDr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities. These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC.

Receive RDY News and Ratings via Email

Sign-up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNYSE:RDY
CUSIPN/A
Phone91-40-4900-2900

Debt

Debt-to-Equity Ratio0.20%
Current Ratio1.46%
Quick Ratio1.08%

Price-To-Earnings

Trailing P/E Ratio37.5440538257653
Forward P/E Ratio33.92
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.17 billion
Price / Sales2.95
Cash Flow$2.19 per share
Price / Cash17.62
Book Value$11.55 per share
Price / Book3.35

Profitability

Trailing EPS$1.03
Net Income$186 million
Net Margins7.91%
Return on Equity9.10%
Return on Assets5.03%

Miscellaneous

EmployeesN/A
Outstanding Shares165,830,000

Dr.Reddy's Laboratories (NYSE:RDY) Frequently Asked Questions

What is Dr.Reddy's Laboratories' stock symbol?

Dr.Reddy's Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "RDY."

How often does Dr.Reddy's Laboratories pay dividends? What is the dividend yield for Dr.Reddy's Laboratories?

Dr.Reddy's Laboratories announced a None dividend on Friday, August 4th. Investors of record on Monday, July 17th will be given a dividend of $0.294 per share on Thursday, August 10th. The ex-dividend date is Thursday, July 13th. View Dr.Reddy's Laboratories' Dividend History.

How were Dr.Reddy's Laboratories' earnings last quarter?

Dr.Reddy's Laboratories Ltd (NYSE:RDY) released its quarterly earnings data on Tuesday, October, 31st. The company reported $0.26 EPS for the quarter. Dr.Reddy's Laboratories had a net margin of 7.91% and a return on equity of 9.10%. View Dr.Reddy's Laboratories' Earnings History.

When will Dr.Reddy's Laboratories make its next earnings announcement?

Dr.Reddy's Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, January, 25th 2018. View Earnings Estimates for Dr.Reddy's Laboratories.

Where is Dr.Reddy's Laboratories' stock going? Where will Dr.Reddy's Laboratories' stock price be in 2018?

4 equities research analysts have issued 12 month price objectives for Dr.Reddy's Laboratories' shares. Their forecasts range from $30.51 to $30.51. On average, they anticipate Dr.Reddy's Laboratories' share price to reach $30.51 in the next year. View Analyst Ratings for Dr.Reddy's Laboratories.

Who are some of Dr.Reddy's Laboratories' key competitors?

Who are Dr.Reddy's Laboratories' key executives?

Dr.Reddy's Laboratories' management team includes the folowing people:

  • Satish K. Reddy, Chairman of the Board (Age 50)
  • G. V. Prasad, Co-Chairman of the Board, Chief Executive Officer, Managing Director (Age 57)
  • Saumen Chakraborty, President, Chief Financial Officer, Global Head - HR and IT & BPE (Age 56)
  • Sripada Chandrasekhar Ph.D., President, Global Head - Human Resources (Age 60)
  • Abhijit Mukherjee, Chief Operating Officer (Age 59)
  • Amit Biswas, Executive Vice President and Head - Integrated Product Development (Age 57)
  • Samiran Das, Executive Vice President and Head - Global Manufacturing Operations (Age 57)
  • Ganadhish Kamat, Executive Vice President and Global Head-Quality (Age 54)
  • J Ramachandran, Executive Vice President-Management Systems and Corporate Initiatives (Age 53)
  • M. V. Ramana, Executive Vice President and Head-Branded Markets - India & Emerging Markets (Age 49)

Who owns Dr.Reddy's Laboratories stock?

Dr.Reddy's Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Mondrian Investment Partners LTD (0.22%), Hexavest Inc. (0.11%) and Bank of Montreal Can (0.09%). View Institutional Ownership Trends for Dr.Reddy's Laboratories.

Who sold Dr.Reddy's Laboratories stock? Who is selling Dr.Reddy's Laboratories stock?

Dr.Reddy's Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. View Insider Buying and Selling for Dr.Reddy's Laboratories.

Who bought Dr.Reddy's Laboratories stock? Who is buying Dr.Reddy's Laboratories stock?

Dr.Reddy's Laboratories' stock was purchased by a variety of institutional investors in the last quarter, including Mondrian Investment Partners LTD and Hexavest Inc.. View Insider Buying and Selling for Dr.Reddy's Laboratories.

How do I buy Dr.Reddy's Laboratories stock?

Shares of Dr.Reddy's Laboratories can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dr.Reddy's Laboratories' stock price today?

One share of Dr.Reddy's Laboratories stock can currently be purchased for approximately $38.67.

How big of a company is Dr.Reddy's Laboratories?

Dr.Reddy's Laboratories has a market capitalization of $6.35 billion and generates $2.17 billion in revenue each year. The company earns $186 million in net income (profit) each year or $1.03 on an earnings per share basis.

How can I contact Dr.Reddy's Laboratories?

Dr.Reddy's Laboratories' mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The company can be reached via phone at 91-40-4900-2900 or via email at [email protected]


MarketBeat Community Rating for Dr.Reddy's Laboratories (RDY)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  113 (Vote Outperform)
Underperform Votes:  165 (Vote Underperform)
Total Votes:  278
MarketBeat's community ratings are surveys of what our community members think about Dr.Reddy's Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Dr.Reddy's Laboratories (NYSE:RDY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldSell
Consensus Rating Score: 2.252.252.251.33
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $30.51$30.51$31.62$41.90
Price Target Upside: 16.11% downside16.11% downside11.38% downside3.84% upside

Dr.Reddy's Laboratories (NYSE:RDY) Consensus Price Target History

Price Target History for Dr.Reddy's Laboratories (NYSE:RDY)

Dr.Reddy's Laboratories (NYSE:RDY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/1/2017Jefferies GroupLower Price TargetUnderperform$31.62 -> $30.51N/AView Rating Details
9/21/2017Morgan StanleyUpgradeEqual Weight -> OverweightLowView Rating Details
8/31/2017CLSAUpgradeUnderperform -> OutperformHighView Rating Details
5/15/2017Deutsche BankUpgradeSell -> HoldHighView Rating Details
7/26/2016Credit Suisse GroupDowngradeNeutral -> UnderperformN/AView Rating Details
5/2/2016Goldman Sachs GroupInitiated CoverageNeutralN/AView Rating Details
(Data available from 1/21/2016 forward)

Earnings

Dr.Reddy's Laboratories (NYSE:RDY) Earnings History and Estimates Chart

Earnings by Quarter for Dr.Reddy's Laboratories (NYSE:RDY)

Dr.Reddy's Laboratories (NYSE RDY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/25/2018N/AView Earnings Details
10/31/2017Q2 2018$0.26ViewN/AView Earnings Details
7/27/2017Q1 2018$0.06ViewN/AView Earnings Details
5/12/2017Q4 2017$0.29ViewN/AView Earnings Details
2/4/2017Q3 2017$0.42ViewN/AView Earnings Details
10/25/2016Q2 2017$0.27ViewN/AView Earnings Details
7/26/2016Q117$0.00$557.00 million$479.00 millionViewListenView Earnings Details
5/12/2016Q416$0.07$2.41 billion$567.00 billionViewListenView Earnings Details
2/9/2016Q316$0.51$2.48 million$599.00 millionViewN/AView Earnings Details
10/29/2015Q116$0.65$2.54 billion$609.00 millionViewListenView Earnings Details
7/30/2015Q1 2016$0.58ViewN/AView Earnings Details
5/12/2015Q415$0.49$559.00 million$621.00 millionViewListenView Earnings Details
1/29/2015Q315$0.53$561.00 million$610.00 millionViewN/AView Earnings Details
10/29/2014Q2 2015$0.54ViewN/AView Earnings Details
7/30/2014Q115$0.54$474.00 million$486.00 millionViewN/AView Earnings Details
5/13/2014Q414$0.52$0.47$557.00 million$580.00 millionViewN/AView Earnings Details
2/11/2014Q314$0.45$0.59$558.20 million$571.00 millionViewN/AView Earnings Details
10/31/2013Q214$0.46$0.65$561.00 million$537.00 millionViewN/AView Earnings Details
7/30/2013Q413$0.43$0.40$551.40 million$478.00 millionViewN/AView Earnings Details
5/14/2013$0.60ViewN/AView Earnings Details
2/14/2013Q313$0.40$505.00 million$522.00 millionViewN/AView Earnings Details
10/30/2012Q2 2013$0.58ViewN/AView Earnings Details
7/19/2012Q1 2013$0.37ViewN/AView Earnings Details
5/11/2012Q4 2012$0.48ViewN/AView Earnings Details
2/3/2012Q3 2012$0.60ViewN/AView Earnings Details
10/25/2011Q2 2012$0.40ViewN/AView Earnings Details
7/20/2011Q1 2012$0.33ViewN/AView Earnings Details
5/13/2011Q4 2011$0.37ViewN/AView Earnings Details
1/25/2011Q3 2011$0.40ViewN/AView Earnings Details
10/23/2010Q2 2011$0.40ViewN/AView Earnings Details
7/22/2010Q1 2011$0.30ViewN/AView Earnings Details
5/6/2010Q4 2010$0.23ViewN/AView Earnings Details
1/20/2010Q3 2010$0.37$0.29ViewN/AView Earnings Details
10/23/2009Q2 2010$0.20$0.30ViewN/AView Earnings Details
7/21/2009Q1 2010$0.30ViewN/AView Earnings Details
5/18/2009Q4 2009$0.33$0.48ViewN/AView Earnings Details
1/20/2009Q3 2009$0.20ViewN/AView Earnings Details
10/23/2008Q2 2009$0.20ViewN/AView Earnings Details
7/21/2008Q1 2009$0.19ViewN/AView Earnings Details
5/20/2008Q4 2008$0.15ViewN/AView Earnings Details
1/25/2008Q3 2008$0.11ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Dr.Reddy's Laboratories (NYSE:RDY) Earnings Estimates

Current Year EPS Consensus Estimate: $1.14 EPS
Next Year EPS Consensus Estimate: $1.88 EPS

Dividends

Dr.Reddy's Laboratories (NYSE:RDY) Dividend Information

Most Recent Dividend:8/10/2017
Annual Dividend:$0.29
Dividend Yield:0.75%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio:28.16% (Trailing 12 Months of Earnings)
25.44% (Based on This Year's Estimates)
15.43% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Dr.Reddy's Laboratories (NYSE:RDY)

Dr.Reddy's Laboratories (NYSE:RDY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/4/2017None$0.297/13/20177/17/20178/10/2017
6/6/2017$0.297/13/20177/17/20177/17/2017
6/6/2016Annual$0.287/14/20167/18/20167/18/2016
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Dr.Reddy's Laboratories (NYSE RDY)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Dr.Reddy's Laboratories (NYSE RDY) News Headlines

Source:
DateHeadline
Dr.Reddy's Laboratories (RDY) to Release Quarterly Earnings on ThursdayDr.Reddy's Laboratories (RDY) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - January 18 at 2:50 AM
Dr. Reddys to release Q3 FY18 results on January 25, 2018Dr. Reddy's to release Q3 FY18 results on January 25, 2018
finance.yahoo.com - January 16 at 8:33 AM
Dr. Reddys Laboratories Limited to Present at the 36th Annual JP Morgan Healthcare Conference - Business Wire (press release)Dr. Reddy's Laboratories Limited to Present at the 36th Annual JP Morgan Healthcare Conference - Business Wire (press release)
www.businesswire.com - January 6 at 3:26 PM
Dr.Reddy's Laboratories Ltd (RDY) Receives Average Recommendation of "Hold" from AnalystsDr.Reddy's Laboratories Ltd (RDY) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 6 at 1:26 AM
Asian ADRs Move Higher in Tuesday Trading - Nasdaq.com - NasdaqAsian ADRs Move Higher in Tuesday Trading - Nasdaq.com - Nasdaq
www.nasdaq.com - January 2 at 3:32 PM
Dr.Reddy's Laboratories (RDY) Upgraded to Hold at Zacks Investment ResearchDr.Reddy's Laboratories (RDY) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - January 2 at 12:00 PM
Bullish Two Hundred Day Moving Average Cross - RDY - Nasdaq.com - NasdaqBullish Two Hundred Day Moving Average Cross - RDY - Nasdaq.com - Nasdaq
www.nasdaq.com - December 30 at 3:26 PM
Dr Reddy’s Laboratories Limited’s (NSE:DRREDDY) Earnings Grew 6.9% In A Year. Was It Better Than Its Long-Term Trend?Dr Reddy’s Laboratories Limited’s (NSE:DRREDDY) Earnings Grew 6.9% In A Year. Was It Better Than Its Long-Term Trend?
finance.yahoo.com - December 30 at 8:40 AM
ETFs with exposure to Dr. Reddy’s Laboratories Ltd. : December 27, 2017ETFs with exposure to Dr. Reddy’s Laboratories Ltd. : December 27, 2017
finance.yahoo.com - December 27 at 3:17 PM
Form 6-K DR REDDYS LABORATORIES For: Dec 26Form 6-K DR REDDYS LABORATORIES For: Dec 26
www.streetinsider.com - December 26 at 11:05 PM
Asian ADRs Move Lower in Tuesday Trading - NasdaqAsian ADRs Move Lower in Tuesday Trading - Nasdaq
www.nasdaq.com - December 26 at 6:02 PM
Health Care Sector Update for 12/26/2017: PTLA, ALXN, ABBV, ZSAN, RDY, NVS - NasdaqHealth Care Sector Update for 12/26/2017: PTLA, ALXN, ABBV, ZSAN, RDY, NVS - Nasdaq
www.nasdaq.com - December 26 at 6:02 PM
Dr. Reddys Labs Launches Melphalan Hydrochloride For Injection In US - NasdaqDr. Reddy's Labs Launches Melphalan Hydrochloride For Injection In US - Nasdaq
www.nasdaq.com - December 26 at 6:02 PM
Dr. Reddy’s Laboratories Ltd. :RDY-US: Earnings Analysis: Q2, 2018 By the Numbers : December 26, 2017Dr. Reddy’s Laboratories Ltd. :RDY-US: Earnings Analysis: Q2, 2018 By the Numbers : December 26, 2017
finance.yahoo.com - December 26 at 1:01 PM
How Do Analysts See Dr Reddy’s Laboratories Limited (NSE:DRREDDY) Performing Over The Couple Of Years?How Do Analysts See Dr Reddy’s Laboratories Limited (NSE:DRREDDY) Performing Over The Couple Of Years?
finance.yahoo.com - December 21 at 8:09 AM
Dr. Reddys announces it has reached a settlement with the US Government regarding companys compliance with the ... - Business Wire (press release)Dr. Reddy's announces it has reached a settlement with the US Government regarding company's compliance with the ... - Business Wire (press release)
www.businesswire.com - December 19 at 8:33 AM
Dr. Reddy’s announces it has reached a settlement with the US Government regarding company’s compliance with the Consumer Product Safety ActDr. Reddy’s announces it has reached a settlement with the US Government regarding company’s compliance with the Consumer Product Safety Act
finance.yahoo.com - December 19 at 8:32 AM
Is Dr Reddy’s Laboratories Limited (NSE:DRREDDY) A Financially Sound Company?Is Dr Reddy’s Laboratories Limited (NSE:DRREDDY) A Financially Sound Company?
finance.yahoo.com - December 12 at 8:43 AM
Dr.Reddy's Laboratories Ltd (RDY) Given Consensus Recommendation of "Hold" by AnalystsDr.Reddy's Laboratories Ltd (RDY) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - December 12 at 1:56 AM
Dr. Reddy’s Announces Approval of Impoyz™ (clobetasol propionate) Cream, 0.025% First-Cycle NDA ApprovalDr. Reddy’s Announces Approval of Impoyz™ (clobetasol propionate) Cream, 0.025% First-Cycle NDA Approval
finance.yahoo.com - December 10 at 3:27 PM
Dr. Reddys Labs (RDY) Announces Approval of Impoyz Cream, 0.025% First-Cycle NDA Approval - StreetInsider.comDr. Reddys Labs (RDY) Announces Approval of Impoyz Cream, 0.025% First-Cycle NDA Approval - StreetInsider.com
www.streetinsider.com - December 1 at 10:47 AM
BRIEF-Dr.Reddys Labs Says U.S. Securities Classs Action Lawsuit Been Served On CoBRIEF-Dr.Reddy's Labs Says U.S. Securities Classs Action Lawsuit Been Served On Co
www.reuters.com - November 29 at 3:24 PM
Exclusive - Prescient messages about Indian companies circulate in WhatsApp groupsExclusive - Prescient messages about Indian companies circulate in WhatsApp groups
finance.yahoo.com - November 21 at 9:46 AM
Exclusive: Prescient messages about Indian companies circulate in WhatsApp groupsExclusive: Prescient messages about Indian companies circulate in WhatsApp groups
finance.yahoo.com - November 18 at 11:17 AM
Dr. Reddys Laboratories Ltd (RDY) Receives Consensus Recommendation of "Hold" from BrokeragesDr. Reddy's Laboratories Ltd (RDY) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 17 at 1:48 AM
Dr. Reddys Laboratories Announces the Launch of Clofarabine Injection in the US Market - Business Wire (press release)Dr. Reddy's Laboratories Announces the Launch of Clofarabine Injection in the US Market - Business Wire (press release)
www.businesswire.com - November 14 at 3:23 PM
Dr. Reddys launches generic Clolar in U.S.Dr. Reddy's launches generic Clolar in U.S.
seekingalpha.com - November 14 at 7:16 AM
Dr. Reddys Launches Therapeutic Equivalent Generic Version Of Clolar InjectionDr. Reddy's Launches Therapeutic Equivalent Generic Version Of Clolar Injection
www.nasdaq.com - November 14 at 7:16 AM
Dr. Reddys Laboratories Announces the Launch of Clofarabine Injection in the U.S. MarketDr. Reddy's Laboratories Announces the Launch of Clofarabine Injection in the U.S. Market
finance.yahoo.com - November 14 at 7:16 AM
VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down - NasdaqVIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down - Nasdaq
www.nasdaq.com - November 9 at 12:20 PM
Jefferies Group Weighs in on Dr. Reddys Laboratories Ltds FY2018 Earnings (RDY)Jefferies Group Weighs in on Dr. Reddy's Laboratories Ltd's FY2018 Earnings (RDY)
www.americanbankingnews.com - November 2 at 3:32 PM
Dr. Reddys Laboratories (RDY) Q2 2018 Results - Earnings Call Transcript - Seeking AlphaDr. Reddy's Laboratories' (RDY) Q2 2018 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 1 at 8:03 AM
Analyzing Neuralstem (CUR) and Dr. Reddys Laboratories (RDY)Analyzing Neuralstem (CUR) and Dr. Reddy's Laboratories (RDY)
www.americanbankingnews.com - October 31 at 9:16 PM
Dr. Reddys Q2 and H1 FY18 Financial Results - Business Wire (press release)Dr. Reddy's Q2 and H1 FY18 Financial Results - Business Wire (press release)
www.businesswire.com - October 31 at 8:30 AM
Dr. Reddy’s Q2 and H1 FY18 Financial ResultsDr. Reddy’s Q2 and H1 FY18 Financial Results
finance.yahoo.com - October 31 at 8:30 AM
Doctor Reddys posts 2Q profitDoctor Reddy's posts 2Q profit
finance.yahoo.com - October 31 at 8:30 AM
Dr. Reddys Laboratories Ltd. Sponsored ADR to Host Earnings CallDr. Reddy's Laboratories Ltd. Sponsored ADR to Host Earnings Call
finance.yahoo.com - October 31 at 8:30 AM
Analyzing Abbott Laboratories (ABT) & Dr. Reddys Laboratories (RDY)Analyzing Abbott Laboratories (ABT) & Dr. Reddy's Laboratories (RDY)
www.americanbankingnews.com - October 28 at 3:32 PM
FY2019 Earnings Estimate for Dr. Reddys Laboratories Ltd (RDY) Issued By Jefferies GroupFY2019 Earnings Estimate for Dr. Reddy's Laboratories Ltd (RDY) Issued By Jefferies Group
www.americanbankingnews.com - October 26 at 4:06 PM
FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Dr. Reddys Laboratories Ltd. (RDY) & Lead Plaintiff Deadline: October 24, 2017FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Dr. Reddy's Laboratories Ltd. (RDY) & Lead Plaintiff Deadline: October 24, 2017
finance.yahoo.com - October 25 at 9:46 AM
DEADLINE TODAY: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy’s Laboratories Limited and Reminds Investors with Losses to Contact the FirmDEADLINE TODAY: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy’s Laboratories Limited and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - October 25 at 9:46 AM
Dr. Reddys Laboratories Ltd (RDY) Set to Announce Earnings on TuesdayDr. Reddy's Laboratories Ltd (RDY) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - October 24 at 1:46 PM
Impax Labs stock surges 4.4% on FDA approval of generic kidney disease medication Renvela - MarketWatchImpax Labs stock surges 4.4% on FDA approval of generic kidney disease medication Renvela - MarketWatch
www.marketwatch.com - October 24 at 9:10 AM
DR. REDDYS 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors of ... - Business Wire (press release)DR. REDDY'S 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors of ... - Business Wire (press release)
www.businesswire.com - October 24 at 9:10 AM
RDY Reminder Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Dr. Reddy’s Laboratories, Ltd.RDY Reminder Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Dr. Reddy’s Laboratories, Ltd.
finance.yahoo.com - October 24 at 9:10 AM
RDY DEADLINE TOMORROW: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Dr. Reddys Laboratories Ltd. and a Lead Plaintiff Deadline of October 24, 2017RDY DEADLINE TOMORROW: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Dr. Reddy's Laboratories Ltd. and a Lead Plaintiff Deadline of October 24, 2017
finance.yahoo.com - October 24 at 9:10 AM
DEADLINE TOMORROW: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddys Laboratories Limited and Reminds Investors with Losses to Contact the FirmDEADLINE TOMORROW: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - October 24 at 9:10 AM
DR. REDDY’S 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors of Deadline in Class Action Lawsuit against Dr. Reddy’s Laboratories Ltd. – (RDY)DR. REDDY’S 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors of Deadline in Class Action Lawsuit against Dr. Reddy’s Laboratories Ltd. – (RDY)
finance.yahoo.com - October 24 at 9:10 AM
DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Dr. Reddy’s Laboratories Ltd. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 24, 2017 - RDYDEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Dr. Reddy’s Laboratories Ltd. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 24, 2017 - RDY
finance.yahoo.com - October 24 at 9:10 AM
Dr. Reddys Laboratories Ltd (RDY) Receives Average Recommendation of "Hold" from BrokeragesDr. Reddy's Laboratories Ltd (RDY) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 23 at 2:06 AM

SEC Filings

Dr.Reddy's Laboratories (NYSE:RDY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Dr.Reddy's Laboratories (NYSE:RDY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Dr.Reddy's Laboratories (NYSE RDY) Stock Chart for Sunday, January, 21, 2018

Loading chart…

This page was last updated on 1/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.